Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100720 | 0.99 | MCHR1 (0.40) | MCHR1HTR2CTGFBR1FYNESR1 | |
| SCHEMBL10100580 | 0.95 | MCHR1 (0.40) | MCHR1HTR2CTGFBR1FYNESR1 | |
| SCHEMBL10100453 | 0.94 | MCHR1 (0.41) | MCHR1HTR2CTGFBR1FYNESR1 | |
| SCHEMBL10100779 | 0.92 | MET (0.43) | TGFBR1FYNPTPN1 | |
| SCHEMBL10100768 | 0.92 | ADORA2A (0.38) | MCHR1HTR2CFYNESR1HTR2A | |
| SCHEMBL10100711 | 0.91 | BMPR1B (0.37) | MCHR1HTR2CTGFBR1FYNESR1 | |
| SCHEMBL10100709 | 0.90 | SMN1; SMN2 (0.38) | HTR2CESR1HTR2AHTR2B | |
| SCHEMBL10100717 | 0.90 | HRH3 (0.36) | MCHR1TGFBR1FYNESR1 | |
| SCHEMBL10100724 | 0.89 | SMN1; SMN2 (0.37) | HTR2CESR1HTR2AHTR2B | |
| SCHEMBL10100716 | 0.89 | ABL1 (0.36) | HTR2CESR1HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | MCHR1 1746/4885HTR2C 2488/4885TGFBR1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.